Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DBVT NASDAQ:KRYS NASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$19.73-1.3%$20.78$7.53▼$26.18$1.11B-0.96225,615 shs127,428 shsKRYSKrystal Biotech$305.71+3.0%$263.06$122.80▼$306.10$8.75B0.5287,707 shs470,347 shsSGMOSangamo Therapeutics$0.12+13.7%$0.30$0.10▼$0.77$47.64M1.049.36 million shs6.98 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies0.00%-4.81%-7.07%-5.97%+110.42%KRYSKrystal Biotech0.00%+13.13%+12.29%+8.78%+116.89%SGMOSangamo Therapeutics0.00%-15.18%-60.31%-74.73%-84.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$19.73-1.3%$20.78$7.53▼$26.18$1.11B-0.96225,615 shs127,428 shsKRYSKrystal Biotech$305.71+3.0%$263.06$122.80▼$306.10$8.75B0.5287,707 shs470,347 shsSGMOSangamo Therapeutics$0.12+13.7%$0.30$0.10▼$0.77$47.64M1.049.36 million shs6.98 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies0.00%-4.81%-7.07%-5.97%+110.42%KRYSKrystal Biotech0.00%+13.13%+12.29%+8.78%+116.89%SGMOSangamo Therapeutics0.00%-15.18%-60.31%-74.73%-84.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVTDBV Technologies 2.67Moderate Buy$40.25104.00% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.116.02% UpsideSGMOSangamo Therapeutics 1.75Reduce$5.504,682.61% UpsideCurrent Analyst Ratings BreakdownLatest SGMO, DBVT, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/4/2026DBVTDBV Technologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$51.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/1/2026DBVTDBV Technologies CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/1/2026DBVTDBV Technologies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$47.00 ➝ $55.004/16/2026SGMOSangamo Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/9/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)3/27/2026DBVTDBV Technologies Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$45.00 ➝ $47.003/27/2026DBVTDBV Technologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$51.003/27/2026KRYSKrystal Biotech Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVTDBV Technologies$5.64M194.75N/AN/A$3.73 per share5.29KRYSKrystal Biotech$389.13M23.16$7.51 per share40.70$43.31 per share7.06SGMOSangamo Therapeutics$39.55M1.20N/AN/A($0.04) per share-2.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVTDBV Technologies-$146.95M-$4.46N/AN/AN/A-2,895.37%-129.88%-88.84%N/AKRYSKrystal Biotech$204.83M$7.4840.8729.06N/A53.92%19.25%17.62%N/ASGMOSangamo Therapeutics-$122.93M-$0.44N/AN/AN/A-310.81%-2,662.06%-132.12%5/11/2026 (Estimated)Latest SGMO, DBVT, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026SGMOSangamo Therapeutics$0.0050N/AN/AN/A$33.73 millionN/A5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million4/30/2026Q4 2025DBVTDBV Technologies-$0.14-$0.56-$0.42-$0.55$1.11 million$0.90 million3/26/2026Q4 2025DBVTDBV Technologies-$0.1935-$1.15-$0.9565-$4.43$1.06 million$0.64 million2/17/2026Q4 2025KRYSKrystal Biotech$1.62$1.70+$0.08$1.70$105.30 million$107.11 million2/14/2026Q4 2025DBVTDBV TechnologiesN/A-$1.15N/A-$1.15N/A$0.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDBVTDBV TechnologiesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVTDBV TechnologiesN/A4.764.76KRYSKrystal BiotechN/A9.469.56SGMOSangamo TherapeuticsN/A0.840.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVTDBV Technologies71.74%KRYSKrystal Biotech86.29%SGMOSangamo Therapeutics56.92%Insider OwnershipCompanyInsider OwnershipDBVTDBV Technologies1.44%KRYSKrystal Biotech13.10%SGMOSangamo Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVTDBV Technologies8055.67 million54.87 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableSGMOSangamo Therapeutics480414.28 million397.29 millionOptionableSGMO, DBVT, and KRYS HeadlinesRecent News About These CompaniesSangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketMay 5, 2026 | finanznachrichten.deSangamo Therapeutics (SGMO) to Release Earnings on MondayMay 4, 2026 | marketbeat.comShort Interest in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Expands By 14.0%May 3, 2026 | americanbankingnews.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest UpdateMay 1, 2026 | marketbeat.comSangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)April 30, 2026 | globenewswire.comSangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB marketApril 29, 2026 | finance.yahoo.comSangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketApril 29, 2026 | globenewswire.comSangamo Therapeutics (NASDAQ:SGMO) Insider Sells $17,456.75 in StockApril 24, 2026 | insidertrades.comGregory Davis Sells 69,827 Shares of Sangamo Therapeutics (NASDAQ:SGMO) StockApril 23, 2026 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) SVP Sells $89,944.92 in StockApril 23, 2026 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks ResearchApril 18, 2026 | marketbeat.comSangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth UncertaintyApril 1, 2026 | tipranks.comSangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsMarch 31, 2026 | finanznachrichten.deWhy PEPG, SGMO, PHR are among top premarket losers todayMarch 31, 2026 | msn.comSangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and ...March 31, 2026 | finance.yahoo.comSangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talksMarch 30, 2026 | seekingalpha.comSangamo: Q4 Earnings SnapshotMarch 30, 2026 | khou.comKSangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comSangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsMarch 30, 2026 | globenewswire.comSangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings CallMarch 19, 2026 | globenewswire.comSangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseMarch 9, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSGMO, DBVT, and KRYS Company DescriptionsDBV Technologies NASDAQ:DBVT$19.73 -0.26 (-1.30%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$19.73 0.00 (0.00%) As of 05/8/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Krystal Biotech NASDAQ:KRYS$305.71 +9.01 (+3.04%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$311.14 +5.43 (+1.78%) As of 05/8/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Sangamo Therapeutics NASDAQ:SGMO$0.12 +0.01 (+13.75%) As of 05/8/2026 03:59 PM EasternSangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
